Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial

The Southeastern Cancer Study Group performed a Phase II study of teniposide in previously treated patients with metastatic breast cancer. No responses were observed in 11 evaluable patients who received teniposide 60 mg/m2 by IV infusion for five consecutive days every three weeks. Toxicity was pri...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1988-04, Vol.6 (1), p.37-40
Main Authors: Cox, E B, Vogel, C L, Carpenter, Jr, J T, Raney, M
Format: Article
Language:English
Subjects:
Adult
Aged
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Drug Evaluation
Drug Resistance
Female
Humans
Middle Aged
Neoplasm Metastasis
Podophyllotoxin - analogs & derivatives
Teniposide - adverse effects
Teniposide - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Southeastern Cancer Study Group performed a Phase II study of teniposide in previously treated patients with metastatic breast cancer. No responses were observed in 11 evaluable patients who received teniposide 60 mg/m2 by IV infusion for five consecutive days every three weeks. Toxicity was primarily gastrointestinal and hematologic and was frequently severe. This study demonstrated no therapeutic activity for teniposide when given in this dose and schedule to patients with heavily pretreated metastatic breast cancer.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00170777